TWI857043B - 用於治療ｋｉｔ及ｐｄｇｆｒａ介導之疾病的組合物及方法 - Google Patents

Info

Publication number

TWI857043B

TWI857043B TW109111858A TW109111858A TWI857043B TW I857043 B TWI857043 B TW I857043B TW 109111858 A TW109111858 A TW 109111858A TW 109111858 A TW109111858 A TW 109111858A TW I857043 B TWI857043 B TW I857043B

Authority

TW

Taiwan

Prior art keywords

compound

mmol

compounds

pharmaceutically acceptable

kit

Prior art date

2019-04-12

Links

• Espacenet
• Global Dossier
• Discuss

• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 59
• 201000010099 disease Diseases 0.000 title claims abstract description 47
• 239000000203 mixture Substances 0.000 title claims description 97
• 238000000034 method Methods 0.000 title abstract description 66
• 230000001404 mediated effect Effects 0.000 title description 12
• 101150038994 PDGFRA gene Proteins 0.000 title description 11
• 150000001875 compounds Chemical class 0.000 claims abstract description 340
• 150000003839 salts Chemical class 0.000 claims abstract description 77
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims abstract description 25
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims abstract description 23
• 208000008589 Obesity Diseases 0.000 claims description 44
• 235000020824 obesity Nutrition 0.000 claims description 43
• 230000009885 systemic effect Effects 0.000 claims description 28
• 239000003814 drug Substances 0.000 claims description 16
• 238000002360 preparation method Methods 0.000 claims description 11
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 208000032839 leukemia Diseases 0.000 claims description 7
• 238000009472 formulation Methods 0.000 claims description 3
• 230000002380 cytological effect Effects 0.000 claims description 2
• 206010020718 hyperplasia Diseases 0.000 claims description 2
• 239000000932 sedative agent Substances 0.000 claims 1
• 230000001624 sedative effect Effects 0.000 claims 1
• 210000004556 brain Anatomy 0.000 abstract description 67
• 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 abstract description 47
• 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 abstract description 47
• 239000012453 solvate Substances 0.000 abstract description 28
• 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
• 239000000243 solution Substances 0.000 description 82
• 238000003786 synthesis reaction Methods 0.000 description 61
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
• 230000015572 biosynthetic process Effects 0.000 description 60
• 230000035772 mutation Effects 0.000 description 59
• 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 58
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 54
• 210000004027 cell Anatomy 0.000 description 51
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
• 239000007787 solid Substances 0.000 description 46
• YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
• 239000012267 brine Substances 0.000 description 42
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 42
• 239000002904 solvent Substances 0.000 description 39
• 238000003818 flash chromatography Methods 0.000 description 37
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
• 239000000741 silica gel Substances 0.000 description 33
• 229910002027 silica gel Inorganic materials 0.000 description 33
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 31
• 241000700159 Rattus Species 0.000 description 31
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
• 239000012071 phase Substances 0.000 description 29
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
• 208000027004 Eosinophilic disease Diseases 0.000 description 28
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
• 239000011541 reaction mixture Substances 0.000 description 24
• 238000005160 1H NMR spectroscopy Methods 0.000 description 22
• 238000006243 chemical reaction Methods 0.000 description 22
• 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 21
• 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 21
• 238000011282 treatment Methods 0.000 description 20
• 239000012044 organic layer Substances 0.000 description 18
• 238000002953 preparative HPLC Methods 0.000 description 18
• 108090000623 proteins and genes Proteins 0.000 description 17
• TVOJIBGZFYMWDT-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CNN=C1 TVOJIBGZFYMWDT-UHFFFAOYSA-N 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 235000019439 ethyl acetate Nutrition 0.000 description 16
• 229910052739 hydrogen Inorganic materials 0.000 description 16
• 239000001257 hydrogen Substances 0.000 description 16
• 102200076881 rs121913507 Human genes 0.000 description 16
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 15
• 102000001253 Protein Kinase Human genes 0.000 description 15
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
• 238000003556 assay Methods 0.000 description 15
• 239000003112 inhibitor Substances 0.000 description 15
• 108060006633 protein kinase Proteins 0.000 description 15
• 235000018102 proteins Nutrition 0.000 description 15
• 102000004169 proteins and genes Human genes 0.000 description 15
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
• 108091000080 Phosphotransferase Proteins 0.000 description 14
• 239000004698 Polyethylene Substances 0.000 description 14
• 238000009739 binding Methods 0.000 description 14
• 239000003208 petroleum Substances 0.000 description 14
• -1 such as -F Chemical group 0.000 description 14
• 208000024891 symptom Diseases 0.000 description 14
• 241000282414 Homo sapiens Species 0.000 description 13
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 13
• 230000027455 binding Effects 0.000 description 13
• 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 13
• 210000003979 eosinophil Anatomy 0.000 description 13
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
• 102000020233 phosphotransferase Human genes 0.000 description 13
• 239000000047 product Substances 0.000 description 13
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 12
• 239000012230 colorless oil Substances 0.000 description 12
• 208000035475 disorder Diseases 0.000 description 12
• 229960002411 imatinib Drugs 0.000 description 12
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 12
• 239000003921 oil Substances 0.000 description 12
• 235000019198 oils Nutrition 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 11
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• FVBWLIPNYGDMCQ-LLVKDONJSA-N 1-[(3R)-oxolan-3-yl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C[C@@H](CC1)N1N=CC(=C1)B1OC(C(O1)(C)C)(C)C FVBWLIPNYGDMCQ-LLVKDONJSA-N 0.000 description 10
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 10
• 206010014958 Eosinophilic leukaemia Diseases 0.000 description 10
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
• 101150068332 KIT gene Proteins 0.000 description 10
• 229960001456 adenosine triphosphate Drugs 0.000 description 10
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
• 108090000765 processed proteins & peptides Proteins 0.000 description 10
• 239000000758 substrate Substances 0.000 description 10
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 9
• 230000020411 cell activation Effects 0.000 description 9
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 9
• 230000002327 eosinophilic effect Effects 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 9
• 239000011734 sodium Substances 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 206010066817 Activation syndrome Diseases 0.000 description 8
• HTSXPGZYHWSIKE-QMKXWPMSSA-N NC(C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1C[C@H](C1)O Chemical compound NC(C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1C[C@H](C1)O HTSXPGZYHWSIKE-QMKXWPMSSA-N 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 102000004196 processed proteins & peptides Human genes 0.000 description 8
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• 208000003950 B-cell lymphoma Diseases 0.000 description 7
• 241000282693 Cercopithecidae Species 0.000 description 7
• 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 7
• RZRKZPNDSMQAAC-PMERELPUSA-N FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C1CCOCC1 Chemical compound FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C1CCOCC1 RZRKZPNDSMQAAC-PMERELPUSA-N 0.000 description 7
• ZNRLUMAQXXGHLH-LJAQVGFWSA-N FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CC1COC1 Chemical compound FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CC1COC1 ZNRLUMAQXXGHLH-LJAQVGFWSA-N 0.000 description 7
• ASTMKBTYHRFVMB-SVEHJYQDSA-N FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1COCC1 Chemical compound FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1COCC1 ASTMKBTYHRFVMB-SVEHJYQDSA-N 0.000 description 7
• ASTMKBTYHRFVMB-IRPSRAIASA-N FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@H]1COCC1 Chemical compound FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@H]1COCC1 ASTMKBTYHRFVMB-IRPSRAIASA-N 0.000 description 7
• 206010073751 Intracranial germ cell tumour Diseases 0.000 description 7
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 7
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 7
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 7
• GHPDUZPCNZVCOV-NDEPHWFRSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C1(CC1)CO Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C1(CC1)CO GHPDUZPCNZVCOV-NDEPHWFRSA-N 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• 201000010208 Seminoma Diseases 0.000 description 7
• 239000013543 active substance Substances 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 7
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 201000001441 melanoma Diseases 0.000 description 7
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 7
• 230000035515 penetration Effects 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 238000010898 silica gel chromatography Methods 0.000 description 7
• ZPXVCUUYYAWRKI-RNFRBKRXSA-N (3S,4R)-4-(4-bromopyrazol-1-yl)oxolan-3-ol Chemical compound O[C@@H]1COC[C@H]1n1cc(Br)cn1 ZPXVCUUYYAWRKI-RNFRBKRXSA-N 0.000 description 6
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 6
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
• 208000003174 Brain Neoplasms Diseases 0.000 description 6
• 208000017667 Chronic Disease Diseases 0.000 description 6
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 6
• 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 6
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
• 208000007033 Dysgerminoma Diseases 0.000 description 6
• 208000006168 Ewing Sarcoma Diseases 0.000 description 6
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 6
• JIASVOREYRNRSN-ZEZDXWPOSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1[C@H](COC1)O Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1[C@H](COC1)O JIASVOREYRNRSN-ZEZDXWPOSA-N 0.000 description 6
• JIASVOREYRNRSN-ALTZYDRJSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@H]1[C@H](COC1)O Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@H]1[C@H](COC1)O JIASVOREYRNRSN-ALTZYDRJSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 125000000217 alkyl group Chemical group 0.000 description 6
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
• 229910000024 caesium carbonate Inorganic materials 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 239000002773 nucleotide Substances 0.000 description 6
• 125000003729 nucleotide group Chemical group 0.000 description 6
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
• 102220197803 rs121913521 Human genes 0.000 description 6
• 238000000926 separation method Methods 0.000 description 6
• 208000011580 syndromic disease Diseases 0.000 description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
• BOOVIFJKQGYEON-UHFFFAOYSA-N 1-(oxan-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C2CCOCC2)N=C1 BOOVIFJKQGYEON-UHFFFAOYSA-N 0.000 description 5
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
• BBIIEKFDAIJTPC-QFIPXVFZSA-N BrC=1C=C2C(=NC=NN2C=1)N1CCN(CC1)C1=NC=C(C=N1)[C@@](C)(N)C1=CC=C(C=C1)F Chemical compound BrC=1C=C2C(=NC=NN2C=1)N1CCN(CC1)C1=NC=C(C=N1)[C@@](C)(N)C1=CC=C(C=C1)F BBIIEKFDAIJTPC-QFIPXVFZSA-N 0.000 description 5
• ZPXVCUUYYAWRKI-NKWVEPMBSA-N BrC=1C=NN(C=1)[C@@H]1[C@@H](COC1)O Chemical compound BrC=1C=NN(C=1)[C@@H]1[C@@H](COC1)O ZPXVCUUYYAWRKI-NKWVEPMBSA-N 0.000 description 5
• 206010020751 Hypersensitivity Diseases 0.000 description 5
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 5
• 239000002138 L01XE21 - Regorafenib Substances 0.000 description 5
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
• 102220473478 Mast/stem cell growth factor receptor Kit_D816F_mutation Human genes 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• FYXLQAOYYVZSSW-UHFFFAOYSA-N NC(C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CC1(CC1)O Chemical compound NC(C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CC1(CC1)O FYXLQAOYYVZSSW-UHFFFAOYSA-N 0.000 description 5
• 208000003251 Pruritus Diseases 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• RUYNTLUDGSFPFZ-UHFFFAOYSA-N cyclobutanol Chemical compound OC1[CH]CC1 RUYNTLUDGSFPFZ-UHFFFAOYSA-N 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 201000001561 eosinophilic gastritis Diseases 0.000 description 5
• ILVAPGLHLXVJIN-UHFFFAOYSA-N ethyl 2-(4-bromopyrazol-1-yl)acetate Chemical compound CCOC(=O)CN1C=C(Br)C=N1 ILVAPGLHLXVJIN-UHFFFAOYSA-N 0.000 description 5
• KUBOWCZIFOSSHE-UHFFFAOYSA-N ethyl 2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)OC(C)(C)C)CC1 KUBOWCZIFOSSHE-UHFFFAOYSA-N 0.000 description 5
• 235000019253 formic acid Nutrition 0.000 description 5
• 125000005843 halogen group Chemical group 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 150000003921 pyrrolotriazines Chemical class 0.000 description 5
• 229960004836 regorafenib Drugs 0.000 description 5
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 5
• 102200076883 rs121913506 Human genes 0.000 description 5
• 210000003491 skin Anatomy 0.000 description 5
• HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
• 238000012453 sprague-dawley rat model Methods 0.000 description 5
• 229960001796 sunitinib Drugs 0.000 description 5
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 5
• VAVNFVOSXKQOAF-UHFFFAOYSA-N tert-butyl 4-[5-[(4-fluorophenyl)methyl]pyrimidin-2-yl]piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)c1ncc(Cc2ccc(F)cc2)cn1 VAVNFVOSXKQOAF-UHFFFAOYSA-N 0.000 description 5
• OWIPJUOXCLFYLH-UHFFFAOYSA-N tert-butyl 4-[5-[methoxy(methyl)carbamoyl]pyrimidin-2-yl]piperazine-1-carboxylate Chemical compound CON(C)C(=O)c1cnc(nc1)N1CCN(CC1)C(=O)OC(C)(C)C OWIPJUOXCLFYLH-UHFFFAOYSA-N 0.000 description 5
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• WVGCPEDBFHEHEZ-UHFFFAOYSA-N 4-bromo-1h-pyrazole Chemical compound BrC=1C=NNC=1 WVGCPEDBFHEHEZ-UHFFFAOYSA-N 0.000 description 4
• UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
• 208000005034 Angiolymphoid Hyperplasia with Eosinophilia Diseases 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 102000004506 Blood Proteins Human genes 0.000 description 4
• 108010017384 Blood Proteins Proteins 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 229910004373 HOAc Inorganic materials 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 4
• 208000014966 Kimura Disease Diseases 0.000 description 4
• 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 4
• 229920001213 Polysorbate 20 Polymers 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
• 210000001185 bone marrow Anatomy 0.000 description 4
• 210000005013 brain tissue Anatomy 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 238000000502 dialysis Methods 0.000 description 4
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 4
• 208000003401 eosinophilic granuloma Diseases 0.000 description 4
• 229910052731 fluorine Inorganic materials 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 229950010895 midostaurin Drugs 0.000 description 4
• BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
• 102200076878 rs121913506 Human genes 0.000 description 4
• 229910052938 sodium sulfate Inorganic materials 0.000 description 4
• 235000011152 sodium sulphate Nutrition 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 239000000454 talc Substances 0.000 description 4
• 229910052623 talc Inorganic materials 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 229920001817 Agar Polymers 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 241000416162 Astragalus gummifer Species 0.000 description 3
• ZPXVCUUYYAWRKI-RQJHMYQMSA-N BrC=1C=NN(C=1)[C@H]1[C@H](COC1)O Chemical compound BrC=1C=NN(C=1)[C@H]1[C@H](COC1)O ZPXVCUUYYAWRKI-RQJHMYQMSA-N 0.000 description 3
• 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 3
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 3
• 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 3
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 239000007832 Na2SO4 Substances 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 229920001615 Tragacanth Polymers 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 210000001789 adipocyte Anatomy 0.000 description 3
• 239000008272 agar Substances 0.000 description 3
• 235000010419 agar Nutrition 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 229910021529 ammonia Inorganic materials 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 230000035578 autophosphorylation Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 239000000440 bentonite Substances 0.000 description 3
• 229910000278 bentonite Inorganic materials 0.000 description 3
• 230000008499 blood brain barrier function Effects 0.000 description 3
• 210000001218 blood-brain barrier Anatomy 0.000 description 3
• 230000006552 constitutive activation Effects 0.000 description 3
• 238000001816 cooling Methods 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 201000000708 eosinophilic esophagitis Diseases 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 3
• 238000004108 freeze drying Methods 0.000 description 3
• 125000000623 heterocyclic group Chemical group 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 230000008595 infiltration Effects 0.000 description 3
• 238000001764 infiltration Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• 206010061289 metastatic neoplasm Diseases 0.000 description 3
• 229940124303 multikinase inhibitor Drugs 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 230000036470 plasma concentration Effects 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 102220197933 rs1057519761 Human genes 0.000 description 3
• 102200076875 rs121913514 Human genes 0.000 description 3
• 102200076877 rs121913682 Human genes 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 235000017550 sodium carbonate Nutrition 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• ORLZAVIAYJERRE-LHAPQZOASA-N tert-butyl 4-[5-[(1S)-1-[[(S)-tert-butylsulfinyl]amino]-1-(4-fluorophenyl)ethyl]pyrimidin-2-yl]piperazine-1-carboxylate Chemical compound C(C)(C)(C)[S@](=O)N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C(=O)OC(C)(C)C ORLZAVIAYJERRE-LHAPQZOASA-N 0.000 description 3
• GDQIOXIBEGTYBZ-POVXSBINSA-N tert-butyl 4-[5-[(Z)-N-[(S)-tert-butylsulfinyl]-C-(4-fluorophenyl)carbonimidoyl]pyrimidin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1c1ncc(C(=N/[S@@](=O)C(C)(C)C)\c2ccc(F)cc2)cn1 GDQIOXIBEGTYBZ-POVXSBINSA-N 0.000 description 3
• VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 3
• 235000010487 tragacanth Nutrition 0.000 description 3
• 239000000196 tragacanth Substances 0.000 description 3
• 229940116362 tragacanth Drugs 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• NLNDDPPILVAYFV-NDEPHWFRSA-N (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine Chemical compound FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)B1OC(C(O1)(C)C)(C)C NLNDDPPILVAYFV-NDEPHWFRSA-N 0.000 description 2
• CGOHFDBJVNRTHG-GHMZBOCLSA-N (1r,2r)-2-phenylmethoxycyclobutan-1-ol Chemical compound O[C@@H]1CC[C@H]1OCC1=CC=CC=C1 CGOHFDBJVNRTHG-GHMZBOCLSA-N 0.000 description 2
• AJYCIRIPANGUFE-SECBINFHSA-N (2R)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propan-1-ol Chemical compound CC1(OB(OC1(C)C)C=1C=NN(C=1)[C@@H](CO)C)C AJYCIRIPANGUFE-SECBINFHSA-N 0.000 description 2
• AJYCIRIPANGUFE-VIFPVBQESA-N (2S)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propan-1-ol Chemical compound CC1(OB(OC1(C)C)C=1C=NN(C=1)[C@H](CO)C)C AJYCIRIPANGUFE-VIFPVBQESA-N 0.000 description 2
• XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 2
• ZMVOVSFKXFUUFU-UHFFFAOYSA-N 1-(oxetan-3-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC1(C)OB(OC1(C)C)c1cnn(CC2COC2)c1 ZMVOVSFKXFUUFU-UHFFFAOYSA-N 0.000 description 2
• PEAJHKJKOQKYJS-OAHLLOKOSA-N 1-[(2R)-1-phenylmethoxypropan-2-yl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C(C1=CC=CC=C1)OC[C@@H](C)N1N=CC(=C1)B1OC(C(O1)(C)C)(C)C PEAJHKJKOQKYJS-OAHLLOKOSA-N 0.000 description 2
• PEAJHKJKOQKYJS-HNNXBMFYSA-N 1-[(2S)-1-phenylmethoxypropan-2-yl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C(C1=CC=CC=C1)OC[C@H](C)N1N=CC(=C1)B1OC(C(O1)(C)C)(C)C PEAJHKJKOQKYJS-HNNXBMFYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• GELKGHVAFRCJNA-UHFFFAOYSA-N 2,2-Dimethyloxirane Chemical compound CC1(C)CO1 GELKGHVAFRCJNA-UHFFFAOYSA-N 0.000 description 2
• QEHDAUWYRNEWBF-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]ethanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CCO)N=C1 QEHDAUWYRNEWBF-UHFFFAOYSA-N 0.000 description 2
• PCCFNCYKKKIXFX-UHFFFAOYSA-N 2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyrimidine-5-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NC=C(C(O)=O)C=N1 PCCFNCYKKKIXFX-UHFFFAOYSA-N 0.000 description 2
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
• UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 2
• 238000012815 AlphaLISA Methods 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• OPVZRBPGXBCXMT-UHFFFAOYSA-N BrC=1C=NN(C=1)CC1(CC1)OC1OCCCC1 Chemical compound BrC=1C=NN(C=1)CC1(CC1)OC1OCCCC1 OPVZRBPGXBCXMT-UHFFFAOYSA-N 0.000 description 2
• XQNHVOMCSCODER-BQBZGAKWSA-N BrC=1C=NN(C=1)[C@@H]1[C@H](CC1)O Chemical compound BrC=1C=NN(C=1)[C@@H]1[C@H](CC1)O XQNHVOMCSCODER-BQBZGAKWSA-N 0.000 description 2
• ZPXVCUUYYAWRKI-BQBZGAKWSA-N BrC=1C=NN(C=1)[C@@H]1[C@H](COC1)O Chemical compound BrC=1C=NN(C=1)[C@@H]1[C@H](COC1)O ZPXVCUUYYAWRKI-BQBZGAKWSA-N 0.000 description 2
• XQNHVOMCSCODER-RNFRBKRXSA-N BrC=1C=NN(C=1)[C@H]1[C@@H](CC1)O Chemical compound BrC=1C=NN(C=1)[C@H]1[C@@H](CC1)O XQNHVOMCSCODER-RNFRBKRXSA-N 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• KTOLJUQGGULYDQ-IYARVYRRSA-N C(C1=CC=CC=C1)O[C@@H]1C[C@H](C1)N1N=CC(=C1)B1OC(C(O1)(C)C)(C)C Chemical compound C(C1=CC=CC=C1)O[C@@H]1C[C@H](C1)N1N=CC(=C1)B1OC(C(O1)(C)C)(C)C KTOLJUQGGULYDQ-IYARVYRRSA-N 0.000 description 2
• WJOBJWXISNIROU-KBPBESRZSA-N C(C1=CC=CC=C1)O[C@@H]1[C@H](CC1)N1N=CC(=C1)Br Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@H](CC1)N1N=CC(=C1)Br WJOBJWXISNIROU-KBPBESRZSA-N 0.000 description 2
• WJOBJWXISNIROU-ZIAGYGMSSA-N C(C1=CC=CC=C1)O[C@H]1[C@@H](CC1)N1N=CC(=C1)Br Chemical compound C(C1=CC=CC=C1)O[C@H]1[C@@H](CC1)N1N=CC(=C1)Br WJOBJWXISNIROU-ZIAGYGMSSA-N 0.000 description 2
• VWLGGDALZZVAQF-XYPYZODXSA-N CC1(OB(OC1(C)C)C=1C=NN(C=1)[C@@H]1C[C@H](C1)O)C Chemical compound CC1(OB(OC1(C)C)C=1C=NN(C=1)[C@@H]1C[C@H](C1)O)C VWLGGDALZZVAQF-XYPYZODXSA-N 0.000 description 2
• OZZFTTRVVCIFDV-QAQDUYKDSA-N CC1=CC=C(C=C1)S(=O)(=O)O[C@@H]1C[C@H](C1)OCC1=CC=CC=C1 Chemical compound CC1=CC=C(C=C1)S(=O)(=O)O[C@@H]1C[C@H](C1)OCC1=CC=CC=C1 OZZFTTRVVCIFDV-QAQDUYKDSA-N 0.000 description 2
• SUJDHOPYTYYIDS-OAHLLOKOSA-N C[C@H](COCC1=CC=CC=C1)OS(=O)(=O)C1=CC=C(C)C=C1 Chemical compound C[C@H](COCC1=CC=CC=C1)OS(=O)(=O)C1=CC=C(C)C=C1 SUJDHOPYTYYIDS-OAHLLOKOSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• OALRVMIKCQLOEW-NTISSMGPSA-N Cl.FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCNCC1 Chemical compound Cl.FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCNCC1 OALRVMIKCQLOEW-NTISSMGPSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 108700024394 Exon Proteins 0.000 description 2
• OMVXHOXLLBHZJZ-UHFFFAOYSA-N FC1=CC=C(C=C1)C(C)(C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CC1(CC1)OC1OCCCC1)N Chemical compound FC1=CC=C(C=C1)C(C)(C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CC1(CC1)OC1OCCCC1)N OMVXHOXLLBHZJZ-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
• HKSQSFRSDPZHNR-PMERELPUSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C(C(=O)OC)(C)C Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C(C(=O)OC)(C)C HKSQSFRSDPZHNR-PMERELPUSA-N 0.000 description 2
• YCWMHZJESHBKHE-LJAQVGFWSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C(CO)(C)C Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C(CO)(C)C YCWMHZJESHBKHE-LJAQVGFWSA-N 0.000 description 2
• GKGYPYUUAKEOMQ-MIUCGUHXSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1[C@H](CC1)O Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1[C@H](CC1)O GKGYPYUUAKEOMQ-MIUCGUHXSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
• 102000001400 Tryptase Human genes 0.000 description 2
• 108060005989 Tryptase Proteins 0.000 description 2
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• SUJDHOPYTYYIDS-HNNXBMFYSA-N [(2s)-1-phenylmethoxypropan-2-yl] 4-methylbenzenesulfonate Chemical compound C([C@H](C)OS(=O)(=O)C=1C=CC(C)=CC=1)OCC1=CC=CC=C1 SUJDHOPYTYYIDS-HNNXBMFYSA-N 0.000 description 2
• KHXQGLSTCGSGLW-RXMQYKEDSA-N [(3r)-oxolan-3-yl] methanesulfonate Chemical compound CS(=O)(=O)O[C@@H]1CCOC1 KHXQGLSTCGSGLW-RXMQYKEDSA-N 0.000 description 2
• KHXQGLSTCGSGLW-YFKPBYRVSA-N [(3s)-oxolan-3-yl] methanesulfonate Chemical compound CS(=O)(=O)O[C@H]1CCOC1 KHXQGLSTCGSGLW-YFKPBYRVSA-N 0.000 description 2
• UCIBJNSKKIUIRM-UHFFFAOYSA-N [1-(4-bromopyrazol-1-yl)cyclopropyl]methanol Chemical compound OCC1(CC1)n1cc(Br)cn1 UCIBJNSKKIUIRM-UHFFFAOYSA-N 0.000 description 2
• QJGOZZPTAGQLCU-QWHCGFSZSA-N [N+](=O)([O-])C1=CC=C(C(=O)O[C@@H]2COC[C@@H]2N2N=CC(=C2)Br)C=C1 Chemical compound [N+](=O)([O-])C1=CC=C(C(=O)O[C@@H]2COC[C@@H]2N2N=CC(=C2)Br)C=C1 QJGOZZPTAGQLCU-QWHCGFSZSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 208000030961 allergic reaction Diseases 0.000 description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 238000010256 biochemical assay Methods 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 238000012754 cardiac puncture Methods 0.000 description 2
• 238000012054 celltiter-glo Methods 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 235000005687 corn oil Nutrition 0.000 description 2
• 239000002285 corn oil Substances 0.000 description 2
• 235000012343 cottonseed oil Nutrition 0.000 description 2
• 239000002385 cottonseed oil Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
• 230000003001 depressive effect Effects 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 230000007783 downstream signaling Effects 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 210000003238 esophagus Anatomy 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 238000011010 flushing procedure Methods 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 125000004438 haloalkoxy group Chemical group 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 150000002431 hydrogen Chemical class 0.000 description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000007794 irritation Effects 0.000 description 2
• 230000007803 itching Effects 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 210000001853 liver microsome Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• MVLGDQOKTMAUKX-UHFFFAOYSA-N methyl 1-(4-bromopyrazol-1-yl)cyclopropane-1-carboxylate Chemical compound COC(=O)C1(CC1)n1cc(Br)cn1 MVLGDQOKTMAUKX-UHFFFAOYSA-N 0.000 description 2
• PQUSVJVVRXWKDG-UHFFFAOYSA-N methyl 2-bromo-2-methylpropanoate Chemical compound COC(=O)C(C)(C)Br PQUSVJVVRXWKDG-UHFFFAOYSA-N 0.000 description 2
• YRXGPNAUFJPKRO-UHFFFAOYSA-N methyl 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propanoate Chemical compound C1=NN(C(C)(C)C(=O)OC)C=C1B1OC(C)(C)C(C)(C)O1 YRXGPNAUFJPKRO-UHFFFAOYSA-N 0.000 description 2
• DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
• 229960003793 midazolam Drugs 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• GSEZHCLWHDZJAB-UHFFFAOYSA-N oxan-4-yl methanesulfonate Chemical compound CS(=O)(=O)OC1CCOCC1 GSEZHCLWHDZJAB-UHFFFAOYSA-N 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 229960001404 quinidine Drugs 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 102200076882 rs1057519709 Human genes 0.000 description 2
• 102220197813 rs1057519710 Human genes 0.000 description 2
• 102220197814 rs1057519711 Human genes 0.000 description 2
• 102200076782 rs1057519713 Human genes 0.000 description 2
• 102220200395 rs1057524681 Human genes 0.000 description 2
• 102220197900 rs121913516 Human genes 0.000 description 2
• 102200076818 rs121913517 Human genes 0.000 description 2
• 102220197808 rs121913523 Human genes 0.000 description 2
• 102220392578 rs74856317 Human genes 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
• 229960003604 testosterone Drugs 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
• AZZHGIGPMAOTAK-VWLOTQADSA-N (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine Chemical compound C[C@](N)(C1=CC=C(F)C=C1)C1=CN=C(N=C1)N1CCN(CC1)C1=NC=NN2C=C(C=C12)C1=CNN=C1 AZZHGIGPMAOTAK-VWLOTQADSA-N 0.000 description 1
• KJBPYIUAQLPHJG-SECBINFHSA-N (2r)-1-phenylmethoxypropan-2-ol Chemical compound C[C@@H](O)COCC1=CC=CC=C1 KJBPYIUAQLPHJG-SECBINFHSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• KJBPYIUAQLPHJG-VIFPVBQESA-N (2s)-1-phenylmethoxypropan-2-ol Chemical compound C[C@H](O)COCC1=CC=CC=C1 KJBPYIUAQLPHJG-VIFPVBQESA-N 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• KIYMAKQVFHPNGB-UHFFFAOYSA-N 1-(oxetan-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C2COC2)N=C1 KIYMAKQVFHPNGB-UHFFFAOYSA-N 0.000 description 1
• MGXMJGKPXMWQIJ-UHFFFAOYSA-N 1-[(4-bromopyrazol-1-yl)methyl]cyclopropan-1-ol Chemical compound C1=C(Br)C=NN1CC1(O)CC1 MGXMJGKPXMWQIJ-UHFFFAOYSA-N 0.000 description 1
• LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
• FLNMQGISZVYIIK-UHFFFAOYSA-N 1-ethylpyrazole Chemical compound CCN1C=CC=N1 FLNMQGISZVYIIK-UHFFFAOYSA-N 0.000 description 1
• LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
• CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
• HRPGUVFWKDCSSX-UHFFFAOYSA-N 2-phenylmethoxycyclobutan-1-one Chemical compound O=C1CCC1OCC1=CC=CC=C1 HRPGUVFWKDCSSX-UHFFFAOYSA-N 0.000 description 1
• LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
• AIUTZIYTEUMXGG-UHFFFAOYSA-N 3,6-dioxabicyclo[3.1.0]hexane Chemical compound C1OCC2OC12 AIUTZIYTEUMXGG-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 1
• ZGSDRBWWICYJBU-UHFFFAOYSA-N 3-phenylmethoxycyclobutan-1-ol Chemical compound C1C(O)CC1OCC1=CC=CC=C1 ZGSDRBWWICYJBU-UHFFFAOYSA-N 0.000 description 1
• OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
• YPMBNJLVUQKSTI-UHFFFAOYSA-N 6-bromo-4-chloropyrrolo[2,1-f][1,2,4]triazine Chemical compound ClC1=NC=NN2C=C(Br)C=C12 YPMBNJLVUQKSTI-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
• 241001251200 Agelas Species 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 241000937413 Axia Species 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• TXEGWKOLVMZYEZ-UHFFFAOYSA-N C(C)C1C(C1)(O)CN1N=CC(=C1)Br Chemical compound C(C)C1C(C1)(O)CN1N=CC(=C1)Br TXEGWKOLVMZYEZ-UHFFFAOYSA-N 0.000 description 1
• 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
• 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
• BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
• 241000255925 Diptera Species 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PRMSOOZEXLRLKJ-NDEPHWFRSA-N FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C1COC1 Chemical compound FC1=CC=C(C=C1)[C@](C)(N)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C1COC1 PRMSOOZEXLRLKJ-NDEPHWFRSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000005577 Gastroenteritis Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101001062093 Homo sapiens RNA-binding protein 15 Proteins 0.000 description 1
• 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
• 101000795074 Homo sapiens Tryptase alpha/beta-1 Proteins 0.000 description 1
• 238000004566 IR spectroscopy Methods 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
• MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 1
• 229910010082 LiAlH Inorganic materials 0.000 description 1
• 229910010084 LiAlH4 Inorganic materials 0.000 description 1
• 102000018247 Lymphocyte-specific proteins Human genes 0.000 description 1
• 108050007388 Lymphocyte-specific proteins Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
• 108090000301 Membrane transport proteins Proteins 0.000 description 1
• 102000003939 Membrane transport proteins Human genes 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• ZDOCYNAMRNTZSX-LJAQVGFWSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CC(C)(O)C Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CC(C)(O)C ZDOCYNAMRNTZSX-LJAQVGFWSA-N 0.000 description 1
• IPMARPMXSFFZFG-MHZLTWQESA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CCO Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CCO IPMARPMXSFFZFG-MHZLTWQESA-N 0.000 description 1
• OPOILSUUPUWPEK-GDJIYFAZSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C[C@@H](C)O Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)C[C@@H](C)O OPOILSUUPUWPEK-GDJIYFAZSA-N 0.000 description 1
• IKNZABOYOGXEHS-GDJIYFAZSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H](CO)C Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H](CO)C IKNZABOYOGXEHS-GDJIYFAZSA-N 0.000 description 1
• JIASVOREYRNRSN-HFASVGIHSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1[C@@H](COC1)O Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@@H]1[C@@H](COC1)O JIASVOREYRNRSN-HFASVGIHSA-N 0.000 description 1
• GKGYPYUUAKEOMQ-YPZXTKLSSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@H]1[C@@H](CC1)O Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@H]1[C@@H](CC1)O GKGYPYUUAKEOMQ-YPZXTKLSSA-N 0.000 description 1
• JIASVOREYRNRSN-GEBXHLAXSA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@H]1[C@@H](COC1)O Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)[C@H]1[C@@H](COC1)O JIASVOREYRNRSN-GEBXHLAXSA-N 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102000012515 Protein kinase domains Human genes 0.000 description 1
• 108050002122 Protein kinase domains Proteins 0.000 description 1
• GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 1
• 102100029244 RNA-binding protein 15 Human genes 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
• GOOHAUXETOMSMM-VKHMYHEASA-N S-propylene oxide Chemical compound C[C@H]1CO1 GOOHAUXETOMSMM-VKHMYHEASA-N 0.000 description 1
• 201000008213 SM-AHNMD Diseases 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 208000032488 Systemic mastocytosis with associated hematologic neoplasm Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102100029639 Tryptase alpha/beta-1 Human genes 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
• 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000009056 active transport Effects 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• 238000003016 alphascreen Methods 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• VMWZRHGIAVCFNS-UHFFFAOYSA-J aluminum;lithium;tetrahydroxide Chemical compound [Li+].[OH-].[OH-].[OH-].[OH-].[Al+3] VMWZRHGIAVCFNS-UHFFFAOYSA-J 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
• 239000000538 analytical sample Substances 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000012148 binding buffer Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 229960000455 brentuximab vedotin Drugs 0.000 description 1
• 239000001273 butane Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 229960001292 cabozantinib Drugs 0.000 description 1
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 239000000378 calcium silicate Substances 0.000 description 1
• 229910052918 calcium silicate Inorganic materials 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 239000003518 caustics Substances 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229950009240 crenolanib Drugs 0.000 description 1
• DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229960001305 cysteine hydrochloride Drugs 0.000 description 1
• 230000002435 cytoreductive effect Effects 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960001985 dextromethorphan Drugs 0.000 description 1
• 230000003205 diastolic effect Effects 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 229950005476 elacridar Drugs 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 206010057271 eosinophilic colitis Diseases 0.000 description 1
• 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
• IEMKQRSOAOPKRJ-UHFFFAOYSA-N ethyl 2-chloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1 IEMKQRSOAOPKRJ-UHFFFAOYSA-N 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
• 125000003709 fluoroalkyl group Chemical group 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 208000024364 idiopathic hypereosinophilic syndrome Diseases 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 229940030980 inova Drugs 0.000 description 1
• 229950000038 interferon alfa Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 206010024378 leukocytosis Diseases 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
• FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• DQHIGEQXJBMKKY-UHFFFAOYSA-N methyl 2,4-dibromobutanoate Chemical compound COC(=O)C(Br)CCBr DQHIGEQXJBMKKY-UHFFFAOYSA-N 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
• 235000018342 monosodium citrate Nutrition 0.000 description 1
• 239000002524 monosodium citrate Substances 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
• OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 description 1
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
• NJDNNGVASRCMGO-UHFFFAOYSA-N oxetan-3-ylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1COC1 NJDNNGVASRCMGO-UHFFFAOYSA-N 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 235000011181 potassium carbonates Nutrition 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
• ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229940121487 ripretinib Drugs 0.000 description 1
• CEFJVGZHQAGLHS-UHFFFAOYSA-N ripretinib Chemical compound O=C1N(CC)C2=CC(NC)=NC=C2C=C1C(C(=CC=1F)Br)=CC=1NC(=O)NC1=CC=CC=C1 CEFJVGZHQAGLHS-UHFFFAOYSA-N 0.000 description 1
• 102220197572 rs1057519392 Human genes 0.000 description 1
• 102220198350 rs121913235 Human genes 0.000 description 1
• 102220197799 rs121913517 Human genes 0.000 description 1
• 102220197801 rs121913521 Human genes 0.000 description 1
• 102200143072 rs9885672 Human genes 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229940100996 sodium bisulfate Drugs 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000011083 sodium citrates Nutrition 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 229940001482 sodium sulfite Drugs 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
• WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 208000026901 systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 238000004885 tandem mass spectrometry Methods 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000607 toxicokinetics Toxicity 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 229940070710 valerate Drugs 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1